New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
March 31 2008 - 4:01PM
PR Newswire (US)
CHICAGO, March 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
(NASDAQ:CVTX) announced today that preclinical research presented
at the American College of Cardiology 57th Annual Scientific
Session in Chicago showed that ranolazine increased
glucose-stimulated insulin secretion (GSIS) in pancreatic islets
isolated from animals and humans. The Company believes that the
increase in GSIS seen with ranolazine may contribute to the
statistically significant reductions in hemoglobin A1c (HbA1c)
levels observed with Ranexa in cardiovascular patients with
diabetes from the phase 3 CARISA (n=189 with angina and diabetes)
and MERLIN-TIMI 36 (n=2,220 with acute coronary syndromes and
diabetes) clinical trials. In CARISA, Ranexa reduced HbA1c levels
by an average of up to 0.7 percentage points. In MERLIN-TIMI 36,
Ranexa lowered HbA1c versus placebo by an average of 0.43
percentage points at four months in patients with a mean baseline
HbA1c level of 7.5%. The preclinical results presented today showed
that ranolazine increased GSIS in a dose-dependent manner in
isolated islets. Acute administration of ranolazine to animals also
significantly increased GSIS in the presence of a glucose load (p
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024